Open AccessRecombinant Tissue-Type Plasminogen Activator Plus Eptifibatide Versus Recombinant Tissue-Type Plasminogen Activator Alone in Acute Ischemic Stroke
Author(s) -
Opeolu Adeoye,
Heidi Sucharew,
Jane Khoury,
Thomas A. Tomsick,
Pooja Khatri,
Yuko Y. Palesch,
Pamela Schmit,
Arthur Pancioli,
Joseph P. Broderick
Publication year - 2014
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.114.006743
Subject(s) - medicine , eptifibatide , stroke (engine) , tissue plasminogen activator , fibrinolytic agent , modified rankin scale , plasminogen activator , randomized controlled trial , t plasminogen activator , thrombolysis , surgery , gastroenterology , ischemic stroke , ischemia , percutaneous coronary intervention , myocardial infarction , mechanical engineering , engineering
The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial demonstrated safety of recombinant tissue-type plasminogen activator (r-tPA) plus eptifibatide in acute ischemic stroke (AIS). CLEAR-ER randomized AIS patients (5:1) to 0.6 mg/kg r-tPA plus eptifibatide versus standard r-tPA (0.9 mg/kg). Interventional Management of Stroke III randomized AIS patients to r-tPA plus endovascular therapy versus standard r-tPA. Albumin in Acute Stroke Part 2 randomized patients to albumin±r-tPA versus saline±r-tPA. Our aim was to compare outcomes in CLEAR-ER combination arm patients to propensity score-matched r-tPA only subjects in Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom